51043-72-2

Usage

Uses

Used in Pharmaceutical Industry:
Dicyclopropylmethylamine hydrochloride is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs and medicinal compounds.
Used in Organic Synthesis:
In the field of organic synthesis, dicyclopropylmethylamine hydrochloride is used as a reagent in chemical reactions. Its ability to participate in a variety of reactions, such as nucleophilic substitutions and addition reactions, makes it a useful building block for the synthesis of complex organic molecules.
Used in Research and Development:
Dicyclopropylmethylamine hydrochloride is utilized in research and development settings as a tool to explore new chemical reactions and pathways. Its distinctive properties and reactivity provide researchers with opportunities to investigate novel synthetic routes and mechanisms.
Used in Laboratory Settings:
As a stable and easily handled hydrochloride salt, dicyclopropylmethylamine hydrochloride is commonly used in laboratory settings for educational purposes and as a component in various experimental procedures. Its clear to pale yellow liquid form and distinctive odor make it easily identifiable and manageable in a controlled environment.

Upstream product

• 1121-37-5 dicyclopropyl ketone 
• 14300-33-5 dicyclopropylmethanol 
• 14937-45-2 cetyltributylphosphonium bromide 
• 1160756-79-5 C₁₁H₂₁NOS 

Relevant academic research and scientific papers

Discovery of 1-amino-5 H-pyrido[4,3-b]indol-4-carboxamide inhibitors of janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders

The JAK-STAT pathway mediates signaling by cytokines, which control survival, proliferation, and differentiation of a variety of cells. In recent years, a single point mutation (V617F) in the tyrosine kinase JAK2 was found to be present with a high incidence in myeloproliferative disorders (MPDs). This mutation led to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks. The genetic, biological, and physiological evidence suggests that JAK2 inhibitors could be effective in treating MPDs. De novo design efforts of new scaffolds identified 1-amino-5H-pyrido[4,3-b]indol-4-carboxamides as a new viable lead series. Subsequent optimization of cell potency, metabolic stability, and off-target activities of the leads led to the discovery of 7-(2-aminopyrimidin-5-yl)-1- {[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b] indole-4-carboxamide (65). Compound 65 is a potent, orally active inhibitor of JAK2 with excellent selectivity, PK profile, and in vivo efficacy in animal models.

Imidazopyridines for the treatment of neurological disorders

Corticotropin releasing factor (CRF) antagonists of formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

Imidazolyl derivatives as corticotropin releasing factor inhibitors

The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

Cyclopropyl based O- and N- and S-protecting groups

The present invention is directed to the use of a cyclopropylmethyl derivative as a protecting group for compounds containing an amino group, carboxy group, amido group, mercapto group or hydroxy group and to the compounds formed having the cyclopropylmethyl moiety as the protecting group.